Pàroli E
Institute of Pharmacology, University of Rome La Sapienza, Italy.
Int J Clin Pharmacol Res. 1993;13 Suppl:1-9.
Chondroprotection is a somewhat new field in the therapy of osteoarthritis, which is designed to improve cartilage repair as well as enhance joint remodeling. It clearly results from both laboratory models as well as from studies on human osteoarthritis, that cartilage contains biological resources to meet the repair of degenerative injuries and inflammation. Interestingly, sulfated glycosaminoglycans from matrix inhibit leukocyte protease and complement-mediated immunological reactions. By fractioning cartilage glycosaminoglycans from Selachus (Matrix), evidence has been obtained that a proper chondroitinsulfate sequence, which is able to inhibit elastase, may be released from cartilage proteoglycans by cleavage of the xyl-ser O-glycosidic bond. Since a number of sulfated glycosaminoglycans have a regulatory function in an array of tissues, attention is drawn to possible regulatory properties of selected sequences of matrix chondroitinsulfate, as far as chondroprotection is concerned.
软骨保护是骨关节炎治疗领域中一个相对较新的方向，旨在促进软骨修复并加强关节重塑。从实验室模型以及对人类骨关节炎的研究中都明确可知，软骨含有生物资源以应对退行性损伤和炎症的修复。有趣的是，来自基质的硫酸化糖胺聚糖可抑制白细胞蛋白酶和补体介导的免疫反应。通过分离姥鲨（基质）的软骨糖胺聚糖，已获得证据表明，一个能够抑制弹性蛋白酶的适当硫酸软骨素序列，可能通过木糖 - 丝氨酸O - 糖苷键的断裂从软骨蛋白聚糖中释放出来。由于许多硫酸化糖胺聚糖在一系列组织中具有调节功能，因此就软骨保护而言，人们开始关注基质硫酸软骨素特定序列可能具有的调节特性。
